DNLI - Denali Therapeutics highlights upcoming 2021 milestones

Biopharmaceutical company Denali Therapeutics ([[DNLI]] +7.5%) highlights pipeline updates and 2021 milestones ahead of the coveted annual J.P. Morgan Healthcare Conference lined up next week.Phase 1b study of LRRK2 inhibitor, DNL151 (BIIB122), collaborating with Biogen, in Parkinson’s disease is complete with late-stage clinical development set to begin by year-end 2021.Results from Phase 1 study of DNL343, EIF2B activator, in healthy volunteers are expected in 1H 2021. Plans to initiate a Phase 1b study of DNL343 in patients with amyotrophic lateral sclerosis in 2H 2021?.Plans to file an IND application for DNL593, an intravenously administered recombinant progranulin biotherapeutic enabled by Denali’s Protein Transport Vehicle, in late 2021.Also says, Late-breaker presentation on 12-week data from Cohort A in Phase 1/2 study of DNL310 (ETV:IDS) in Hunter syndrome (MPS II) to be held at WORLD Symposium in February.

For further details see:

Denali Therapeutics highlights upcoming 2021 milestones